DE602006003320D1 - Herstellung eines substituierten chinoxalins von hoher reinheit - Google Patents

Herstellung eines substituierten chinoxalins von hoher reinheit

Info

Publication number
DE602006003320D1
DE602006003320D1 DE602006003320T DE602006003320T DE602006003320D1 DE 602006003320 D1 DE602006003320 D1 DE 602006003320D1 DE 602006003320 T DE602006003320 T DE 602006003320T DE 602006003320 T DE602006003320 T DE 602006003320T DE 602006003320 D1 DE602006003320 D1 DE 602006003320D1
Authority
DE
Germany
Prior art keywords
preparation
substituted
chinoxaline
high purity
cyclization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602006003320T
Other languages
English (en)
Inventor
Frank Robert Busch
Joel Michael Hawkins
Lasson G Mustakis
Terry Gene Sinay Jr
Timothy J N Watson
Groton Withbroe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE602006003320D1 publication Critical patent/DE602006003320D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602006003320T 2005-02-24 2006-02-21 Herstellung eines substituierten chinoxalins von hoher reinheit Expired - Fee Related DE602006003320D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65629605P 2005-02-24 2005-02-24
PCT/IB2006/000351 WO2006090236A1 (en) 2005-02-24 2006-02-21 Preparation of high purity substituted quinoxaline

Publications (1)

Publication Number Publication Date
DE602006003320D1 true DE602006003320D1 (de) 2008-12-04

Family

ID=36405938

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006003320T Expired - Fee Related DE602006003320D1 (de) 2005-02-24 2006-02-21 Herstellung eines substituierten chinoxalins von hoher reinheit

Country Status (15)

Country Link
US (1) US20080275051A1 (de)
EP (1) EP1866308B1 (de)
JP (1) JP2008531540A (de)
KR (1) KR20070098942A (de)
CN (1) CN101128462A (de)
AT (1) ATE411994T1 (de)
AU (1) AU2006217616A1 (de)
BR (1) BRPI0607838A2 (de)
CA (1) CA2598533A1 (de)
DE (1) DE602006003320D1 (de)
ES (1) ES2313625T3 (de)
IL (1) IL185013A0 (de)
MX (1) MX2007010375A (de)
RU (1) RU2007131535A (de)
WO (1) WO2006090236A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527907A (ja) 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
US20120277433A1 (en) * 2009-12-29 2012-11-01 Mahendranath Rao Narasimha Rao Process for the preparation of substituted quinoxalines
EP2545054A1 (de) * 2010-03-09 2013-01-16 Actavis Group Ptc Ehf Hochreines vareniclin oder weitgehend von methylvareniclinunreihheiten freies pharmazeutisch akzeptables salz daraus
US20120004239A1 (en) * 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN114349701B (zh) * 2022-01-07 2024-04-05 江苏豪森药业集团有限公司 一种酒石酸伐尼克兰中间体的制备方法
EP4241775A1 (de) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablette mit vareniclin und verfahren zur herstellung davon
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814592B1 (pt) * 1997-12-31 2010-06-01 composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
HU229867B1 (en) * 2001-05-14 2014-10-28 Pfizer Prod Inc Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
DE602004015986D1 (de) * 2003-06-04 2008-10-02 Pfizer Prod Inc Herstellung von substituierten chinoxalinen aus den dianilinen mit 2,3-dihydroxy-1,4-dioxan

Also Published As

Publication number Publication date
EP1866308B1 (de) 2008-10-22
KR20070098942A (ko) 2007-10-05
ES2313625T3 (es) 2009-03-01
CN101128462A (zh) 2008-02-20
AU2006217616A1 (en) 2006-08-31
CA2598533A1 (en) 2006-08-31
EP1866308A1 (de) 2007-12-19
BRPI0607838A2 (pt) 2009-06-13
WO2006090236A1 (en) 2006-08-31
JP2008531540A (ja) 2008-08-14
RU2007131535A (ru) 2009-03-27
MX2007010375A (es) 2007-09-25
US20080275051A1 (en) 2008-11-06
IL185013A0 (en) 2007-12-03
ATE411994T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
ATE411994T1 (de) Herstellung eines substituierten chinoxalins von hoher reinheit
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
MX2007014172A (es) Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
EA201170132A1 (ru) 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов
EA201101099A1 (ru) Гербициды, полученные из циклопентадиона
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
UA106880C2 (uk) Нові гербіциди
TN2010000045A1 (en) Novel herbicides
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
CY1110688T1 (el) Διεργασια για την παρασκευη καρβεδιλολης και εναντιομερων αυτης
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
ATE503767T1 (de) Herstellung eines von willenbrand faktor- präparates mit hoher spezifischer aktivität
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
DE602006005349D1 (de) Verfahren zur herstellung von hydrazon-derivaten
UY29879A1 (es) Derivados de 6-heteroarilpiridoindolona, su preparación y su aplicación en terapéutica
MX2007013872A (es) Procedimiento para la produccion de 4-bifenililazetidina-2-onas.
NO20065157L (no) Biotransformasjon av colchicinoidforbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee